Trial of AD113 and Atomoxetine in OSA Patients With Hypertension
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, 2-period, non placebo-controlled crossover study in
patients with moderate to severe OSA and controlled hypertension, comparing atomoxetine with
AD113